2f8c
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:2f8c.gif|left|200px]] | [[Image:2f8c.gif|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_2f8c", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | + | or leave the SCENE parameter empty for the default display. | |
| - | + | --> | |
| - | + | {{STRUCTURE_2f8c| PDB=2f8c | SCENE= }} | |
| - | + | ||
| - | + | ||
| - | }} | + | |
'''Crystal structure of FPPS in complex with Zoledronate''' | '''Crystal structure of FPPS in complex with Zoledronate''' | ||
| Line 37: | Line 34: | ||
[[Category: Rondeau, J M.]] | [[Category: Rondeau, J M.]] | ||
[[Category: Strauss, A.]] | [[Category: Strauss, A.]] | ||
| - | [[Category: | + | [[Category: Bisphosphonate inhibitor]] |
| - | [[Category: | + | [[Category: Cholesterol biosynthesis]] |
| - | [[Category: | + | [[Category: Isoprene biosynthesis]] |
| - | [[Category: | + | [[Category: Mevalonate pathway]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 03:35:01 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 00:35, 4 May 2008
Crystal structure of FPPS in complex with Zoledronate
Overview
To understand the structural basis for bisphosphonate therapy of bone diseases, we solved the crystal structures of human farnesyl pyrophosphate synthase (FPPS) in its unliganded state, in complex with the nitrogen-containing bisphosphonate (N-BP) drugs zoledronate, pamidronate, alendronate, and ibandronate, and in the ternary complex with zoledronate and the substrate isopentenyl pyrophosphate (IPP). By revealing three structural snapshots of the enzyme catalytic cycle, each associated with a distinct conformational state, and details about the interactions with N-BPs, these structures provide a novel understanding of the mechanism of FPPS catalysis and inhibition. In particular, the accumulating substrate, IPP, was found to bind to and stabilize the FPPS-N-BP complexes rather than to compete with and displace the N-BP inhibitor. Stabilization of the FPPS-N-BP complex through IPP binding is supported by differential scanning calorimetry analyses of a set of representative N-BPs. Among other factors such as high binding affinity for bone mineral, this particular mode of FPPS inhibition contributes to the exceptional in vivo efficacy of N-BP drugs. Moreover, our data form the basis for structure-guided design of optimized N-BPs with improved pharmacological properties.
About this Structure
2F8C is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs., Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W, ChemMedChem. 2006 Feb;1(2):267-73. PMID:16892359 Page seeded by OCA on Sun May 4 03:35:01 2008
Categories: Homo sapiens | Single protein | Bitsch, F. | Bourgier, E. | Geiser, M. | Green, J R. | Hemmig, R. | Jahnke, W. | Kroemer, M. | Lehmann, S. | Ramage, P. | Rieffel, S. | Rondeau, J M. | Strauss, A. | Bisphosphonate inhibitor | Cholesterol biosynthesis | Isoprene biosynthesis | Mevalonate pathway
